This project will add up to the 74 people already employed at the Artesyn Biosolutions facility acquired by Repligen in 2020.
Repligen Corporation is undergoing an expansion of its Waterford site which will see to create 130 new jobs. .
The life sciences company is building a new 3,000 sq m facility which will be a centre of excellence for single-use consumable products used in bioprocessing applications. The site currently hosts a 1,000 sq m facility employing 74 people, which was established by Ireland’s Artesyn Biosolutions before that company was aquired by Regligion in November of 2020
Repligen is a multinational that produces bioprocessing products for use in the pharmaceutical manufacturing process. Headquartered in Massachusetts, the company has sites across the United States and in Estonia, France, Germany, Sweden and the Netherlands, as well as here in Ireland.
According to the company, the new building will be certified silver on the Leadership in Energy and Environmental Design (LEED) rating system from the US Green Building Council. The consumable products manufactured there will be used in filtration and chromatography systems during the production of vaccines and other biopharmaceutical products.
Commenting on the announcement, Leo Varadkar said: “This is excellent news from Repligen with the creation of 130 new jobs in Waterford. Waterford is on the move as a centre for jobs and investment.
This build-out is an important step in expanding capacity and establishing dual manufacturing sites for key single-use consumable products used in manufacture of biological drugs.
Dr Jonathan Downey, managing director at the Waterford facility, said: “Having delivered beyond our commitment in 2019 to bring new jobs to the region through our development of high-end manufacturing capabilities, we are energised and excited about our integration with Repligen and this next phase of growth.
Source : Silicon Republic https://www.siliconrepublic.com/